Black & White Peptides Ltd. Registered in England & Wales, company number 16876162.
Research category
GHRH & GH Secretagogue Research Peptides
UK supplier of nine compounds spanning the GHRH receptor agonists, ghrelin-mimetic GH secretagogues, the GH peptide itself, and IGF-1 analogues. From the canonical GHRH(1-29) reference Sermorelin to the long-acting CJC 1295 with DAC and the selective ghrelin-mimetic Ipamorelin. Every batch independently HPLC-verified by Janoshik Analytical at 99%+ purity. Research use only – not for human consumption.
Two Classes Under One Category
The “GH-axis” research family splits cleanly into two pharmacological classes that are often studied together:
- GHRH receptor agonists – synthetic analogues of native growth-hormone-releasing hormone, acting on the GHRH receptor on pituitary somatotrophs to stimulate endogenous GH secretion. (Sermorelin, CJC 1295 with/without DAC, Tesamorelin)
- Ghrelin-mimetic GH secretagogues (GHS) – synthetic peptides acting on the growth-hormone secretagogue receptor (GHS-R), the natural target of ghrelin. (Ipamorelin, GHRP-2, GHRP-6)
The two classes act on distinct receptors but converge on the same downstream output: pulsatile GH release. Research literature commonly studies them in combination (“GHRH + GHS”) because the two pulses synergise.
The category also includes the GH peptide itself (HGH/Somatropin, 191 AA recombinant) and the long-arg-3 IGF-1 analogue (IGF-1 LR3) for downstream-axis research.
The Nine Compounds at a Glance
| Compound | Class | Half-life (literature) | Receptor |
|---|---|---|---|
| Sermorelin | GHRH(1-29) native fragment | ~10–20 min | GHRH-R |
| CJC 1295 (DAC) | Modified GHRH + albumin binding | ~6–8 days | GHRH-R |
| CJC 1295 (no DAC) | Modified GRF 1-29 | ~30 min | GHRH-R |
| Tesamorelin | GHRH(1-44) + hexenoyl modification | ~25–40 min | GHRH-R |
| Ipamorelin | Selective ghrelin-mimetic pentapeptide | ~2 hr | GHS-R |
| GHRP-2 | Ghrelin-mimetic hexapeptide | ~15–60 min | GHS-R |
| GHRP-6 | Ghrelin-mimetic hexapeptide | ~15–60 min | GHS-R |
| HGH (Somatropin) | Recombinant 191-AA GH | ~2–4 hr | GH-R |
| IGF-1 LR3 | Long Arg³ IGF-1 analogue | ~20–30 hr | IGF-1R |
GHRH Receptor Agonists
The GHRH-R class is unified by sequence homology to native GHRH(1-29). The four compounds in our catalogue differ primarily in pharmacokinetic profile:
- Sermorelin – the native unmodified GHRH(1-29) fragment. ~10-20 min half-life. Most-cited reference for GHRH receptor pharmacology in published research.
- CJC 1295 without DAC (Modified GRF 1-29) – same backbone as DAC version but no maleimide. ~30 min half-life. Studied as the “improved Sermorelin” reference.
- CJC 1295 with DAC – albumin-bound via Lys³⁰(MPA). ~6-8 day half-life. Reference for long-acting GHRH analogue research.
- Tesamorelin – 44-residue GHRH analogue with N-terminal hexenoyl group. Approved (Egrifta) for HIV-associated lipodystrophy research applications.
Direct comparisons:
- CJC 1295 with DAC vs without DAC
- CJC 1295 (DAC) vs Sermorelin
Ghrelin-Mimetic GH Secretagogues
The GHS class acts on a different receptor (GHS-R / ghrelin receptor) but produces a synergistic downstream GH pulse. Our three compounds:
- Ipamorelin – selective pentapeptide GHS-R agonist with minimal cortisol/prolactin effect in published research. Reference for “clean” ghrelin-mimetic studies.
- GHRP-2 – hexapeptide GHS-R agonist. Higher GH-secretion potency than GHRP-6 in published comparisons; some cortisol/prolactin signal.
- GHRP-6 – the original synthetic GH-releasing peptide. Hexapeptide, similar profile to GHRP-2 with slightly different appetite-pathway signal.
Direct comparisons:
- GHRP-2 vs GHRP-6
- Ipamorelin vs CJC 1295 (no DAC) – ghrelin-mimetic vs GHRH analogue.
The GH Peptide and IGF-1 Analogue
HGH (Somatropin) is the recombinant 191-amino-acid human growth hormone. The downstream effector that GHRH and GHS compounds stimulate. Used in research as the direct GH-receptor reference.
IGF-1 LR3 is a long-arg-3 analogue of insulin-like growth factor 1, with a 13-residue N-terminal extension and Arg³ substitution that reduces IGFBP binding. Reference for IGF-1 receptor research with extended pharmacokinetic profile.
Selection Criteria
GHRH-receptor pharmacology research
Sermorelin is the canonical reference. Use long-acting analogues (CJC 1295 DAC, Tesamorelin) for sustained-stimulation studies.
GHS-R pharmacology research
Ipamorelin for selective ghrelin-mimetic research; GHRP-2 or GHRP-6 for less-selective comparator work.
Combined GHRH + GHS research
Common protocols pair Sermorelin or CJC 1295 (no DAC) with Ipamorelin to study synergistic GH-pulse research signals.
Direct GH or IGF-1 receptor research
HGH (Somatropin) for GH-R studies; IGF-1 LR3 for IGF-1R research with extended half-life.
Laboratory Handling
All compounds in this category are supplied as lyophilised powder in sealed glass vials. Reconstitute with bacteriostatic water added slowly down the side wall, swirling gently. Use the on-site Reconstitution Volume Calculator for mg/mL maths.
- Lyophilised solid: stable 24+ months at 2–8 °C.
- Reconstituted: 14–30 days at 2–8 °C (compound-specific).
- HGH and IGF-1 LR3 reconstituted solutions are particularly sensitive – see compound page.
Purity & Verification
Compounds in this category are independently HPLC-verified by Janoshik Analytical at 99%+ purity. Where a Janoshik report has been issued for the current batch it is supplied with the order, and verification records are published on the Purity page.